Articles

Find an Article

Filter articles

Showing 511 to 520 of 691 results

The bitter pill of fake medicine

International30-01-2015

The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it.

Global patents: innovation leads to growth

International30-01-2015Bob Stembridge

Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.

After Alice: the two-step rule

US30-01-2015Judith Kim and Scott Schaller

Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe.

Marketing authorisation: the right to challenge

EU19-12-2014Trevor Cook

A decision by the CJEU on a Latvian case should make it easier in the future to challenge an MA granted for a generic version of a reference product, as Trevor Cook of WilmerHale explains.

Repurposed drugs: second time lucky

EU19-12-2014Simon Kremer and Rachel Jones

Bringing a ‘repurposed’ drug to market requires a clear patent strategy, but clarity is unfortunately lacking in this field, say Simon Kremer and Rachel Jones of law firm Mewburn Ellis.

Bulletproofing pharma patents

US19-12-2014Christine Goddard and Janis Fraser

Maximising the strength of patent protection should be an important objective of any R&D pharma company. Christine Goddard and Janis Fraser of law firm Fish & Richardson offer their six top tips for success.

Crystallics: crystal clear

UK28-11-2014

With its roots stretching back to oil company Shell, Crystallics underpins pharmaceutical research and development by investigating the crystalline structures of drugs and potential drug compounds. LSIPR reports.

Nagoya Protocol: searching for living gold

EU, UK28-11-2014Charles Brabin

Does the coming into force of the Nagoya Protocol represent an overdue step in the right direction towards fairness, or more red tape and unattainable expectations? Charles Brabin, a non-practising barrister, sifts through the complexities.

University of Manchester IP: walk the line

UK, US28-11-2014

By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line.

Wearable technology: seeing the future

US27-11-2014

Google’s new contact lens sensor is just one of the latest eye-based devices that has vast potential in the field of medicine. LSIPR reports.

Showing 511 to 520 of 691 results

LSIPR